SkillsMechanism: Age-related decline in CTα activity reduces de novo phosphatidylcholine synthesis, leading to plasmalogen deficit and increased homocysteine, causing synaptic vulnerability. Readout: Readout: Intervention with cytidine or CTα activators restores plasmalogen-PC levels, lowers homocysteine, and attenuates memory deficits in aged mice.
Hypothesis Statement
We propose that the rate‑limiting enzyme of the Kennedy pathway, CTP:phosphocholine cytidylyltransferase (CTα), undergoes progressive activity loss with advancing age due to oxidative modification and reduced allosteric activation by phosphatidic acid. This decline diminishes de novo phosphatidylcholine (PC) synthesis, forcing neurons to rely more heavily on the Lands cycle for PC remodeling. The Lands cycle preferentially incorporates exogenous fatty acids, many of which are saturated or monounsaturated, and fails to generate the ethanolamine‑plasmalogen PC species that are depleted in Alzheimer's brains [5]. Consequently, membrane microdomains lose plasmalogen‑mediated antioxidant protection, rendering synaptic vesicles vulnerable to oxidative stress and promoting amyloid‑beta aggregation.
Parallel to membrane defects, reduced flux through the Kennedy pathway limits the availability of choline for betaine synthesis via choline dehydrogenase. Betaine is a methyl donor for the betaine‑homocysteine methyltransferase (BHMT) reaction that remethylates homocysteine to methionine. Lower betaine levels therefore raise plasma homocysteine, a neurotoxin that exacerbates tau phosphorylation and endothelial dysfunction [2]. The combined impact of plasmalogen loss and homocysteine elevation creates a feed‑forward loop: oxidative stress further inhibits CTα, while homocysteine‑induced ER stress impairs phosphatidylcholine biosynthesis.
Testable Predictions
-
Enzyme Activity Gradient – Postmortem human cortical samples will show a negative correlation between donor age and CTα activity, measurable by radiometric conversion of phosphocholine to CDP‑choline, independent of total CTα protein levels (which may remain stable) [4].
-
Lands Cycle Shift – Lipidomics will reveal an increased ratio of lyso‑PC to PC and a decreased proportion of plasmalogen‑PC species in the same samples, correlating with CTα activity decline.
-
Biomarker Cascade – In cognitively normal older adults, peripheral blood betaine will inversely predict homocysteine levels and will positively correlate with CSF plasmalogen‑PC concentrations; both relationships will weaken in individuals with mild cognitive impairment.
-
Intervention Rescue – Administration of cytidine (a downstream product of the Kennedy pathway) or a CTα allosteric activator in aged APP/PS1 mice will restore PC synthesis, normalize plasmalogen‑PC levels, lower homocysteine, and attenuate memory deficits without altering amyloid‑beta production directly.
Falsifiability
If CTα activity does not decline with age, or if augmenting cytidine fails to improve plasmalogen‑PC or homocysteine metrics despite restored CDP‑choline synthesis, the hypothesis would be refuted. Conversely, confirming the predicted enzymatic, lipidomic, and metabolic changes would support a mechanistic bridge between epidemiological choline deficits and the molecular onset of Alzheimer's pathology.
References (inline)
[1] https://www.rezilirhealth.com/blog/choline-and-brain-aging/ [2] https://news.asu.edu/20230117-study-explores-effects-dietary-choline-deficiency-neurologic-systemwide-health [3] https://pubmed.ncbi.nlm.nih.gov/29178478/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC4293825/ [5] https://www.jarlife.net/3844-choline-sleep-disturbances-and-alzheimers-disease.html
Comments
Sign in to comment.